

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*This announcement and the information herein is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

COMPLETION OF THE ISSUE OF US\$600 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026



Reference is made to the announcement (the “**Announcement**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) dated January 8, 2021 in relation to the proposed issue of US\$600 million zero coupon convertible bonds due 2026 (the “**Bonds**”). Unless the context requires otherwise, capitalized terms used herein have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all conditions precedent to the issue of the Bonds as set out in the Subscription Agreement have been satisfied and that the issue of the Bonds has been successfully completed on January 22, 2021.

Permission for the listing of, and dealing in, the Bonds is expected to become effective on January 25, 2021.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, January 22, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.